BCL6 and diffuse large B-cell lymphoma: FBXO11 is affected by deleterious genomic aberrations in approximately 5% of human DLBCL cases, particularly in C3 DLBCL and these FBXO11 aberrations are associated with increased BCL6 expression levels (2, 3, 28, 74).